Prof Peter Schmid speaks to ecancer about the updates on the findings of event-free survival (EFS) sensitivity and subgroup analyses from the KEYNOTE-522 study.

This was a Phase III trial evaluating neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo in early-stage triple-negative breast cancer (TNBC).

He initially explains the background and methodology of the study. Describing the results he says that EFS sensitivity analyses show a robust treatment benefit of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for previously untreated non-metastatic TNBC.

This benefit was generally consistent across a broad selection of patient subgroups. He concludes by discussing the impact of these results on the future treatment of triple-negative breast cancer.